Table 1 Patient characteristics and clinical outcome
Recipient 1 | Recipient 2 | Recipient 3 | Recipient 4 | Recipient 5 | Recipient 6 | |
|---|---|---|---|---|---|---|
Recipient age (yr) | 40 | 33 | 62 | 64 | 50 | 45 |
Recipient sex | Female | Male | Male | Male | Male | Male |
Initial disease | Hypertensive nephropathy | IgA Nephropathy | IgA Nephropathy | Hypertensive nephropathy | Hypertensive nephropathy | Vesicoureteral reflux + left kidney atrophy |
Dialysis (months) | 0 | 0 | 54 | 0 | 0 | 0 |
Donor age (yr) | 44 | 39 | 61 | 50 | 49 | 49 |
PRA | 0 | 0 | 0 | 0 | 0 | 0 |
Renal biopsy 3 mo | Not performed | Not performed | Not performed | Not performed | Normal | Normal |
SCr at 3 mo (mg/dl) | 1.4 mg/dL | 1.5 mg/dL | 1.7 mg/dL | 1.2 mg/dL | 1.6 mg/dL | 1.3 mg/dL |
eGFR (mL/min/1.73 m2) | 44 | 57 | 44 | 65 | 49 | 63 |
Biopsy at 1 year | Not performed | Not performed | Not performed | Not performed | Normal | Normal |
SCr at 1 yr | 1.2 mg/dl | 1.4 mg/dl | 1.6 mg/dl | 1.2 mg/dl | 1.3 mg/dl | 1.2 mg/dl |
eGFR (mL/min/1.73 m2) | 53 | 62 | 47 | 65 | 62 | 69 |
Follow-up (mo) | 121 | 98 | 96 | 54 | 38 | 33 |
Renal function at last follow-up: | ||||||
SCr at last follow-up (mg/dL) | 1.3 mg/dl | 1.3 mg/dl | 1.2 mg/dl | 1.1 mg/dl | 1.4 mg/dl | 1.3 mg/dl |
eGFR (mL/min/1.73 m2) | 47 | 66 | 61 | 71 | 58 | 66 |
Treatment at last follow-up | Mycophenolate mofetil 750 mg/12 h + Irbesartan 300 mg/24 h + Saccharate iron oxide 40 mg/24 h. | Mycophenolate sodium 720 mg/12 h + Bisoprolol 10 mg/24 h + Ranitidine 300 mg/12 h. | Mycophenolate mofetil 1000 mg/12 h + Irbesartan 300 mg/24 h + Levothyroxine 50 mcg/24 h + Atorvastatin 20 mg/24 h + Pantoprazole 40 mg/24 h. | Mycophenolate mofetil 1000 mg/12 h + Telmisartan 40 mg/24 h + Repaglidina 0.5 mg/12 h + Acenocoumarol + Pantoprazole 40 mg/24 h + Benzbromarone 100 mg/24 h. | Mycophenolate sodium 720 mg/12 h + Acetylsalicylic acid 100 mg/24 h + Pantoprazole 20 mg/24 h + Bromazepam 3 mg/24 h. | Mycophenolate mofetil 1000 mg/12 h |